CHRNA5 Antibody (Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P30532 |
---|---|
Clone Names | 100430108 |
Gene ID | 1138 |
---|---|
Other Names | Neuronal acetylcholine receptor subunit alpha-5, CHRNA5, NACHRA5 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP14006c was selected from the Center region of CHRNA5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CHRNA5 |
---|---|
Synonyms | NACHRA5 |
Function | After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. |
Cellular Location | Postsynaptic cell membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a nicotinicacetylcholine receptor subunit and a member of a superfamily ofligand-gated ion channels that mediate fast signal transmission atsynapses. These receptors are thought to be heteropentamerscomposed of separate but similar subunits. Defects in this genehave been linked to susceptibility to lung cancer type 2 (LNCR2).
References
Wessel, J., et al. Neuropsychopharmacology 35(12):2392-2402(2010)Erlich, P.M., et al. Hum. Genet. 128(5):491-499(2010)Shimada, M., et al. Hum. Genet. 128(4):433-441(2010)Falvella, F.S., et al. J. Natl. Cancer Inst. 102(17):1366-1370(2010)Li, M.D., et al. PLoS ONE 5 (8), E12183 (2010) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.